Page last updated: 2024-11-04

temozolomide and Drug Refractory Epilepsy

temozolomide has been researched along with Drug Refractory Epilepsy in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Perampanel (PER) is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoaxazolepropionate acid receptor antagonist that has recently been approved for treating focal epilepsy as a secondary drug of choice."5.56Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy. ( Chonan, M; Kanamori, M; Nakasato, N; Osawa, SI; Saito, R; Suzuki, H; Tominaga, T; Watanabe, M, 2020)
"Perampanel (PER) is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoaxazolepropionate acid receptor antagonist that has recently been approved for treating focal epilepsy as a secondary drug of choice."1.56Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy. ( Chonan, M; Kanamori, M; Nakasato, N; Osawa, SI; Saito, R; Suzuki, H; Tominaga, T; Watanabe, M, 2020)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chonan, M1
Saito, R1
Kanamori, M1
Osawa, SI1
Watanabe, M1
Suzuki, H1
Nakasato, N1
Tominaga, T1

Other Studies

1 other study available for temozolomide and Drug Refractory Epilepsy

ArticleYear
Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
    Neurologia medico-chirurgica, 2020, Jan-15, Volume: 60, Issue:1

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo

2020